Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

James Scott +44 207 848 0002
james.1.scott@kcl.ac.uk


Guy Gitlin-Leigh guy.1.gitlin-leigh@kcl.ac.uk


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia

The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia

Recruiting

Open to: ALL

Age: 18.0 - N/A

Medical Conditions

Schizophrenia
Schizophrenia, Treatment-Resistant


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The goal of this basic science study is to to explore the responsivity of glutamate in the brain of treatment-resistant schizophrenia patients to the drug riluzole. The main aims of the study are:

To assess the role of glutamate in treatment-resistant schizophrenia using magnetic resonance spectroscopy.

To assess the relationship between glutamate levels and brain structural and functional measures (using: structural MRI; functional MRI (fMRI) and arterial spin labelling (ASL)) at baseline.

To assess the relationship between longitudinal change in glutamate levels and brain structural and functional measures.

To assess the relationship between longitudinal change in glutamate levels and changes in psychopathology.

The researchers will compare the changes with healthy controls and those without treatment-resistant schizophrenia.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Nov 2022 Dec 2024

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : 50mg twice daily (100mg total daily) for 56 days.

Intervention Arm Group : Treatment-resistant schizophrenia patients receiving riluzole;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Institute of Psychiatry, Psychology and Neuroscience
    London
    SE5 8AB


The study is sponsored by King's College London and is in collaboration with South London and Maudsley NHS Foundation Trust.




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT06270108
Last updated 04 March 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.